The low density lipoprotein (LDL) receptor is a transmembrane glycoprotein performing "receptor-mediated endocytosis" of cholesterol-rich lipoproteins. At the N terminus, the LDL receptor has modular cysteine-rich repeats in both the ligand binding domain and the epidermal growth factor (EGF) precursor homology domain. Each repeat contains six disulfide-bonded cysteine residues, and this structural motif has also been found in many other proteins. The bovine LDL receptor has been purified and reconstituted into egg yolk phosphatidylcholine vesicle bilayers. Using gel electrophoresis and cryoelectron microscopy (cryoEM), the ability of the reconstituted LDL receptor to bind its ligand LDL has been demonstrated. After reduction of the disulfidebonds in the N-terminal domain of the receptor, the reduced LDL receptor was visualized using cryoEM; reduced LDL receptors showed images with a diffuse density region at the distal end of the extracellular domain. Gold labeling of the reduced cysteine residues was achieved with monomaleimido-Nanogold, and the bound Nanogold was visualized in cryoEM images of the reduced, gold-labeled receptor. Multiple gold particles were observed in the diffuse density region at the distal end of the receptor. Thus, the location of the ligand binding domain of the LDL receptor has been determined, and a model is suggested for the arrangement of the seven cysteine-rich repeats of the ligand binding domain and two EGF-like cysteine-rich repeats of the EGF precursor homology domain.
The low density lipoprotein (LDL)1 receptor binds cholesterol-rich lipoproteins for receptor-mediated endocytosis and plays a key role in the regulation of cholesterol metabolism. This 115-kDa receptor has a mosaic structure containing five distinguishable domains based originally on the sequence of the human LDL receptor (1); the sequences of LDL receptor from other species also suggest the same domain organization (2-7). These domains, beginning at the N terminus are (i) ligand binding domain, (ii) epidermal growth factor (EGF) precursor homology domain, (iii) O-linked sugar domain, (iv) transmembrane domain, and (v) cytoplasmic domain. The ligand binding domain has the characteristic 7 cysteine-rich repeats consisting of a highly homologous 40-residue amino acid sequence. A study using mutated receptors found that different combinations of the cysteine-rich repeats was responsible for binding to LDL or -migrating very low density lipoprotein (-VLDL), both ligands for the LDL receptor (8). Mutations deleting one of the third to the seventh repeats in the ligand binding domain of the LDL receptor resulted in a marked reduction in LDL binding. -VLDL binding to the LDL receptor was decreased only by deletion of the fifth cysteinerich repeat in the ligand binding domain. LDL contains a single high molecular mass (550 kDa) protein, apoB 100 (9), whereas -VLDL has multiple copies of the smaller (33 kDa) apoE plus one molecule of apoB 100 or apoB 48 (10). It is thought that the receptor binding domain of apoB 100 o...